RCUS

Arcus Biosciences, Inc.

NYSEUSDEQUITY DELAYED

30.34

▲ 0.82 (2.78%)

MARKET · —

Price

Open

29.52

Prev close

29.52

Day high

30.56

Day low

29.74

Volume

890.80K

Market cap

—

P/E (TTM)

—

52W range

10.07 – 31.74

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.92% +4.3%

+2.05% -1.7%

+27.11% +24.0%

+59.77% +48.7%

YTD

+27.32% +15.0%

+200.69% +180.7%

+71.41% -2.8%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

29.40

+3.18% from price

SMA 20

28.64

+5.92% from price

SMA 50

28.33

+7.11% from price

SMA 100

26.20

+15.82% from price

SMA 200

24.10

+25.89% from price

EMA 12

29.37

+3.31% from price

EMA 26

28.85

+5.16% from price

EMA 50

28.05

+8.17% from price

RSI (14)

60.1

Neutral

MACD (12,26,9)

0.52

Hist 0.14

ATR (14)

1.25

4.13% of price

Realised vol 30D

43.8%

Annualised

Bollinger upper

30.62

20, 2σ

Bollinger lower

26.67

20, 2σ

50 / 200 cross

Golden

28.33 vs 24.10

Trend bias

Above 200

+25.89%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.78

More volatile than market

Correlation to SPY

0.37

Loosely linked

Realised vol 30D

43.8%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-27.8%

Peak to trough

Max drawdown 5Y

-85.8%

Peak to trough

ATR 14

1.25

4.13% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 30.34

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

RCUS · links out to the publisher

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? Insider Monkey · 9d ago Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript Motley Fool · 10d ago Arcus Biosciences Announces New Employment Inducement Grants Business Wire · 11d ago Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says MT Newswires · 12d ago Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating MT Newswires · 12d ago Arcus Biosciences Q2 Earnings Call Highlights MarketBeat · 14d ago Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism Simply Wall St. · 14d ago Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating MT Newswires · 16d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.